Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany.
Department of Neuropathology, University of Heidelberg Medical Center, Heidelberg, Germany.
Neuro Oncol. 2018 Oct 9;20(11):1517-1524. doi: 10.1093/neuonc/noy134.
This study aims to evaluate the impact of tumor location on key molecular alterations on a single voxel level in patients with newly diagnosed glioma.
A consecutive series of n = 237 patients with newly diagnosed glioblastoma and n = 131 patients with lower-grade glioma was analyzed. Volumetric tumor segmentation was performed on preoperative MRI with a semi-automated approach and images were registered to the standard Montreal Neurological Institute 152 space. Using a voxel-based lesion symptom mapping (VLSM) analysis, we identified specific brain regions that were associated with tumor-specific molecular alterations. We assessed a predefined set of n = 17 molecular characteristics in the glioblastoma cohort and n = 2 molecular characteristics in the lower-grade glioma cohort. Permutation adjustment (n = 1000 iterations) was used to correct for multiple testing, and voxel t-values that were greater than the t-value in >95% of the permutations were retained in the VLSM results (α = 0.05, power > 0.8).
Tumor location predilection for isocitrate dehydrogenase (IDH) mutant tumors was found in both glioblastoma and lower-grade glioma cohorts, each showing a concordant predominance in the frontal lobe adjacent to the rostral extension of the lateral ventricles (permutation-adjusted P = 0.021 for the glioblastoma and 0.013 for the lower-grade glioma cohort). Apart from that, the VLSM analysis did not reveal a significant association of the tumor location with any other key molecular alteration in both cohorts (permutation-adjusted P > 0.05 each).
Our study highlights the unique properties of IDH mutations and underpins the hypothesis that the rostral extension of the lateral ventricles is a potential location for the cell of origin in IDH-mutant gliomas.
本研究旨在评估肿瘤位置对新诊断为脑胶质瘤患者单一体素水平关键分子改变的影响。
分析了连续的 237 例新诊断为胶质母细胞瘤患者和 131 例低级别胶质瘤患者的病例。采用半自动方法对术前 MRI 进行容积肿瘤分割,并将图像注册到标准的蒙特利尔神经学研究所 152 空间。使用基于体素的病变症状映射 (VLSM) 分析,我们确定了与肿瘤特异性分子改变相关的特定脑区。我们评估了胶质母细胞瘤队列中的 n = 17 个分子特征和低级别胶质瘤队列中的 n = 2 个分子特征。采用置换调整(n = 1000 次迭代)校正多重检验,保留 VLSM 结果中大于 95%置换次数的 t 值的体素(α = 0.05,功效> 0.8)。
在胶质母细胞瘤和低级别胶质瘤队列中都发现了异柠檬酸脱氢酶 (IDH) 突变肿瘤的肿瘤位置偏好,每个队列都在靠近侧脑室颅端延伸的额叶中表现出一致的优势(胶质母细胞瘤的置换调整 P = 0.021,低级别胶质瘤队列的 P = 0.013)。除此之外,VLSM 分析在两个队列中均未发现肿瘤位置与任何其他关键分子改变之间存在显著关联(置换调整 P > 0.05 每个)。
本研究强调了 IDH 突变的独特性质,并支持了侧脑室颅端延伸可能是 IDH 突变型胶质瘤起源细胞的潜在位置的假说。